Pipeline — registered trials by phase
Geographic Atrophy Long-Terms Outcomes Study
— · Geographic Atrophy · Completed · est. 2023-07-31
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
— · Geographic Atrophy · Active Not Recruiting · est. 2027-06
Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.
— · Paroxysmal Nocturnal Hemoglobinuria · Completed · est. 2019-08-26
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
— · Geographic Atrophy · Completed · est. 2021-04-01
Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal Pegcetacoplan (APL-2) for Patients With Wet AMD
— · Neovascular Age-Related Macular Degeneration · Completed · est. 2016-03-08
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
— · Paroxysmal Nocturnal Hemoglobinuria (PNH) · Completed · est. 2018-10-22
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
— · PNH · Completed · est. 2019-10-22
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
— · IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy · Completed · est. 2020-04-16
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
— · Geographic Atrophy · Completed · est. 2017-07-14
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
— · Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria · Recruiting · est. 2028-12
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
— · Geographic Atrophy Secondary to Age-related Macular Degeneration · Recruiting · est. 2027-06-25
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
— · COVID, Covid-19, Coronavirus · Completed · est. 2021-02-13
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
— · C3G, IC-MPGN, Renal Transplant · Completed · est. 2023-02-27
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
— · Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease · Completed · est. 2022-09-12
Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe
— · Geographic Atrophy Secondary to Age-related Macular Degeneration · Completed · est. 2025-12-12
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
— · Geographic Atrophy · Completed · est. 2021-06-28
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
— · C3G, IC-MPGN, C3 Glomerulopathy · Active Not Recruiting · est. 2027-07
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
— · FSGS · Recruiting · est. 2029-10
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
— · Geographic Atrophy · Completed · est. 2021-06-21
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
— · C3G, IC-MPGN, C3 Glomerulopathy · Completed · est. 2024-06-26
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH
— · Paroxysmal Nocturnal Hemoglobinuria · Completed · est. 2021-06-23
Pegcetacoplan Long Term Safety and Efficacy Extension Study
— · PNH · Completed · est. 2025-09-04
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
— · Geographic Atrophy Secondary to Age-related Macular Degeneration · Completed · est. 2025-09-05
Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
— · Paroxysmal Nocturnal Hemoglobinuria · Completed · est. 2019-11-14
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Apellis is lead sponsor; 24 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- No filings found.
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.